NHS Branded Medicines Tranche Framework for London and South of England
Who
| Buyer | NHS England — not a council we hold |
| Supplier | Accord-UK Ltd |
| Supplier | AstraZeneca |
| Supplier | Aventis Pharma ltd t/a Sanofi |
| Supplier | Biogen |
| Supplier | BIOSIMILAR COLLABORATIONS IRELAND LIMITED |
| Supplier | Celltrion Healthcare United Kingdom Limited |
| Supplier | Chugai Pharma UK Ltd |
| Supplier | Dr.Reddy's Laboratories (UK) Limited |
| Supplier | Eli Lilly & Company Ltd |
| Supplier | Galapagos Biotech Ltd |
| Supplier | Gedeon Richter UK Ltd |
| Supplier | GlaxoSmithKline UK Limited |
| Supplier | Janssen-Cilag Ltd |
| Supplier | LEO Pharma |
| Supplier | Manx Healthcare Ltd |
| Supplier | Merck Sharpe & Dohme (UK) Limited |
| Supplier | Napp Pharmaceuticals Ltd |
| Supplier | Novartis Pharmaceuticals UK Ltd |
| Supplier | Organon Pharmaceuticals UK Ltd |
| Supplier | Orifarm UK |
| Supplier | Pfizer Ltd |
| Supplier | Roche Products Ltd |
| Supplier | Sobi (Swedish Orphan Biovitrum Ltd) |
| Supplier | Sun Pharma UK Ltd |
| Supplier | Takeda UK Ltd |
| Supplier | Teva UK Limited |
| Supplier | Thornton and Ross Ltd |
| Supplier | UCB Pharma Ltd (primary) |
| Supplier | Zentiva Pharma UK Ltd |
What
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Dates and source
| Runs | 1 Sep 2024 to 31 Aug 2026 |
| OCID | ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c |
| Notice | Read it on Contracts Finder |
Figures are as published An award value in OCDS may be a framework ceiling rather than a sum anyone expects to spend, so a large figure here is not evidence of a large purchase.